Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 8, Issue 10, 2014, Pages 1166-1178

  Rieder, Florian ^a   de Bruyn, Jessica R ^b   Pham, Bao Tung ^c   Katsanos, Konstantinos ^d   Annese, Vito ^e   Higgins, Peter D R ^f   Magro, Fernando ^g,i   Dotan, Iris ^h,j  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF PORTO   (Portugal)

^h TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

ⁱ HOSPITAL DE SÃO JOÃO   (Portugal)

^j TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

Biomarkers; Crohn's disease; ; Fibrosis; ; Inflammatory bowel diseases; ; Ulcerative colitis;

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; GROWTH FACTOR; MICRORNA; PROTEOME; STROMELYSIN;

BODY FLUID; CELL ASSAY; CLINICAL EVALUATION; ENDOSCOPY; GENETIC MARKER; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINAL FIBROSIS; INTESTINE MUCOSA; KIDNEY FIBROSIS; LIVER BIOPSY; LIVER FIBROSIS; LUNG FIBROSIS; MEDICAL RESEARCH; MEDICAL SOCIETY; PHENOTYPE; PROTEIN ANALYSIS; RADIOLOGY; REVIEW; RNA ANALYSIS; SKIN FIBROSIS; WORKSHOP; BLOOD; CHEMISTRY; FIBROSIS; GASTROINTESTINAL ENDOSCOPY; GENETICS; INTESTINE; KIDNEY; LIVER CIRRHOSIS; LUNG LAVAGE; METABOLISM; PATHOLOGY; RADIOGRAPHY; SKIN;

BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; ENDOSCOPY, GASTROINTESTINAL; FIBROSIS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; KIDNEY; LIVER CIRRHOSIS; PROTEOME; PULMONARY FIBROSIS; SKIN;

EID: 84908227294     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.03.009     Document Type: Review

References (121)

1. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis Jul 2002, 8(4):244-250.
2. Gumaste V., Sachar D.B., Greenstein A.J. Benign and malignant colorectal strictures in ulcerative colitis. Gut Jul 1992, 33(7):938-941.
3. Louis E., Michel V., Hugot J.P., Reenaers C., Fontaine F., Delforge M., et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut Apr 2003, 52(4):552-557.
4. Farmer R.G., Whelan G., Fazio V.W. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology Jun 1985, 88(6):1818-1825.
5. Fazio V.W., Tjandra J.J., Lavery I.C., Church J.M., Milsom J.W., Oakley J.R. Long-term follow-up of strictureplasty in Crohn's disease. Dis Colon Rectum Apr 1993, 36(4):355-361.
6. Rieder F. The gut microbiome in intestinal fibrosis: environmental protector or provocateur?. Sci Transl Med Jun 19 2013, 5(190):190ps10.
7. Adler J., Rangwalla S.C., Dwamena B.A., Higgins P.D. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol Apr 2011, 106(4):699-712.
8. Meijer M.J., Mieremet-Ooms M.A., van Hogezand R.A., Lamers C.B., Hommes D.W., Verspaget H.W. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol Jun 7 2007, 13(21):2960-2966.
9. Henckaerts L., Van Steen K., Verstreken I., Cleynen I., Franke A., Schreiber S., et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol Sep 2009, 7(9):972-980.
10. Weersma R.K., Stokkers P.C., Cleynen I., Wolfkamp S.C., Henckaerts L., Schreiber S., et al. Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol Mar 2009, 104(3):630-638.
11. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., Cosnes J. Predictors of Crohn's disease. Gastroenterology Mar 2006, 130(3):650-656.
12. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol Sep 2005, 19(Suppl. A):5A-36A.
13. Dotan I., Fishman S., Dgani Y., Schwartz M., Karban A., Lerner A., et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology Aug 2006, 131(2):366-378.
14. Dubinsky M.C., Lin Y.C., Dutridge D., Picornell Y., Landers C.J., Farrior S., et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol Feb 2006, 101(2):360-367.
15. Rieder F., Lawrance I.C., Leite A., Sans M. Predictors of fibrostenotic Crohn's disease. Inflamm Bowel Dis Sep 2011, 17(9):2000-2007.
16. Kjeldsen J., Schaffalitzky de Muckadell O.B., Junker P. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy. Gut Dec 1995, 37(6):805-810.
17. Koutroubakis I.E., Petinaki E., Dimoulios P., Vardas E., Roussomoustakaki M., Maniatis A.N., et al. Serum laminin and collagen IV in inflammatory bowel disease. J Clin Pathol Nov 2003, 56(11):817-820.
18. Loeschke K., Kaltenthaler P. Procollagen-III-peptide in the serum of patients with Crohn disease. Z Gastroenterol Mar 1989, 27(3):137-139.
19. Allan A., Wyke J., Allan R.N., Morel P., Robinson M., Scott D.L., et al. Plasma fibronectin in Crohn's disease. Gut May 1989, 30(5):627-633.
20. Di S.A., Ciccocioppo R., Armellini E., Morera R., Ricevuti L., Cazzola P., et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis Sep 2004, 10(5):573-577.
21. Rockey D.C., Caldwell S.H., Goodman Z.D., Nelson R.C., Smith A.D. Liver biopsy. Hepatology Mar 2009, 49(3):1017-1044.
22. Duarte-Rojo A., Altamirano J.T., Feld J.J. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Ann Hepatol Jul 2012, 11(4):426-439.
23. Parkes J., Guha I.N., Roderick P., Harris S., Cross R., Manos M.M., et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat Jan 2011, 18(1):23-31.
24. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology Dec 2004, 127(6):1704-1713.
25. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology May 2012, 142(6):1293-1302.
26. Ladero J.M., Cardenas M.C., Ortega L., Gonzalez-Pino A., Cuenca F., Morales C., et al. Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C?. Ann Hepatol Sep 2012, 11(5):648-651.
27. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol May 2008, 48(5):835-847.
28. Tsochatzis E.A., Gurusamy K.S., Ntaoula S., Cholongitas E., Davidson B.R., Burroughs A.K. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol Apr 2011, 54(4):650-659.
29. Huwart L., Sempoux C., Vicaut E., Salameh N., Annet L., Danse E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology Jul 2008, 135(1):32-40.
30. Yin M., Talwalkar J.A., Glaser K.J., Manduca A., Grimm R.C., Rossman P.J., et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol Oct 2007, 5(10):1207-1213.
31. Boursier J., de Ledinghen V., Zarski J.P., Rousselet M.C., Sturm N., Foucher J., et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol Jul 2011, 106(7):1255-1263.
32. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med Jan 15 2002, 165(2):277-304.
33. Cicchitto G., Sanguinetti C.M. Idiopathic pulmonary fibrosis: the need for early diagnosis. Multidiscip Respir Med 2013, 8(1):53.
34. Rosas I.O., Richards T.J., Konishi K., Zhang Y., Gibson K., Lokshin A.E., et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med Apr 29 2008, 5(4):e93.
35. Prasse A., Probst C., Bargagli E., Zissel G., Toews G.B., Flaherty K.R., et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med Apr 15 2009, 179(8):717-723.
36. Furuhashi K., Suda T., Nakamura Y., Inui N., Hashimoto D., Miwa S., et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med Aug 2010, 104(8):1204-1210.
37. Korthagen N.M., van Moorsel C.H., Barlo N.P., Ruven H.J., Kruit A., Heron M., et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med Jan 2011, 105(1):106-113.
38. Kadota J., Mizunoe S., Mito K., Mukae H., Yoshioka S., Kawakami K., et al. High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir Med Jan 2005, 99(1):111-117.
39. Pardo A., Gibson K., Cisneros J., Richards T.J., Yang Y., Becerril C., et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med Sep 2005, 2(9):e251.
40. Okamoto M., Hoshino T., Kitasato Y., Sakazaki Y., Kawayama T., Fujimoto K., et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J May 2011, 37(5):1119-1127.
41. Kono M., Nakamura Y., Suda T., Kato M., Kaida Y., Hashimoto D., et al. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta Nov 20 2011, 412(23-24):2211-2215.
42. Huang H., Peng X., Nakajima J. Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan. Biosci Trends Aug 2013, 7(4):172-177.
43. Zhang Y., Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med Sep 2012, 18(5):441-446.
44. Moeller A., Gilpin S.E., Ask K., Cox G., Cook D., Gauldie J., et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med Apr 1 2009, 179(7):588-594.
45. Gilani S.R., Vuga L.J., Lindell K.O., Gibson K.F., Xue J., Kaminski N., et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of with idiopathic pulmonary fibrosis. PLoS One 2010, 5(1):e8959.
46. + regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med Jun 15 2009, 179(12):1121-1130.
47. Vij R., Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res Apr 2012, 159(4):218-227.
48. Dziadzio M., Usinger W., Leask A., Abraham D., Black C.M., Denton C., et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM Jul 2005, 98(7):485-492.
49. Hesselstrand R., Kassner A., Heinegard D., Saxne T. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis Sep 2008, 67(9):1242-1248.
50. Kim W.U., Min S.Y., Cho M.L., Hong K.H., Shin Y.J., Park S.H., et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 2005, 7(1):R71-R79.
51. Lorenzen J.M., Kramer R., Meier M., Werfel T., Wichmann K., Hoeper M.M., et al. Osteopontin in the development of systemic sclerosis-relation to disease activity and organ manifestation. Rheumatology (Oxford) Oct 2010, 49(10):1989-1991.
52. Macko R.F., Gelber A.C., Young B.A., Lowitt M.H., White B., Wigley F.M., et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol Dec 2002, 29(12):2565-2570.
53. Kikuchi K., Ihn H., Sato S., Igarashi A., Soma Y., Ishibashi Y., et al. Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis. Arch Dermatol Res 1994, 286(2):77-80.
54. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum Jan 2007, 56(1):323-333.
55. Nagy Z., Czirjak L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol Mar 2005, 23(2):165-172.
56. Kikuchi K., Kubo M., Sato S., Fujimoto M., Tamaki K. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol Dec 1995, 33(6):973-978.
57. Codullo V., Baldwin H.M., Singh M.D., Fraser A.R., Wilson C., Gilmour A., et al. An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis Jun 2011, 70(6):1115-1121.
58. Giacomelli R., Cipriani P., Lattanzio R., Di F.M., Locanto M., Parzanese I., et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol Apr 1997, 108(1):42-46.
59. Sato S., Hasegawa M., Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci Oct 2001, 27(2):140-146.
60. Sato S., Fujimoto M., Hasegawa M., Komura K., Yanaba K., Hayakawa I., et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) Oct 2004, 43(10):1261-1266.
61. Kissin E.Y., Merkel P.A., Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum Nov 2006, 54(11):3655-3660.
62. Lafyatis R., Kissin E., York M., Farina G., Viger K., Fritzler M.J., et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum Feb 2009, 60(2):578-583.
63. Rodnan G.P., Lipinski E., Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum Feb 1979, 22(2):130-140.
64. Madani G., Katz R.D., Haddock J.A., Denton C.P., Bell J.R. The role of radiology in the management of systemic sclerosis. Clin Radiol Sep 2008, 63(9):959-967.
65. Moore T.L., Lunt M., McManus B., Anderson M.E., Herrick A.L. Seventeen-point dermal ultrasound scoring system-a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology (Oxford) Dec 2003, 42(12):1559-1563.
66. Lafyatis R. Application of biomarkers to clinical trials in systemic sclerosis. Curr Rheumatol Rep Feb 2012, 14(1):47-55.
67. Moinzadeh P., Denton C.P., Abraham D., Ong V., Hunzelmann N., Eckes B., et al. Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol Mar 2012, 26(3):267-276.
68. Cheng O., Thuillier R., Sampson E., Schultz G., Ruiz P., Zhang X., et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant Oct 2006, 6(10):2292-2306.
69. Gilbert R.E., Akdeniz A., Weitz S., Usinger W.R., Molineaux C., Jones S.E., et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care Sep 2003, 26(9):2632-2636.
70. Io H., Hamada C., Fukui M., Horikoshi S., Tomino Y. Relationship between levels of urinary type IV collagen and renal injuries in patients with IgA nephropathy. J Clin Lab Anal 2004, 18(1):14-18.
71. Tsakas S., Goumenos D.S. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 2006, 26(2):186-193.
72. Torii K., Kimura H., Li X., Okada T., Imura T., Oida K., et al. Diabetic nephropathy and plasminogen activator inhibitor 1 in urine samples. Rinsho Byori Jun 2004, 52(6):506-512.
73. Sugiura T., Wada A. Resistive index predicts renal prognosis in chronic kidney disease. Nephrol Dial Transplant Sep 2009, 24(9):2780-2785.
74. Zhu Y.Z., Cui F.Y., Yang Y., Peng H., Li W.P., Huang Z.D., et al. Optimized pregelatinized starch technique for cell block preparation in cell cultures. Exp Mol Pathol Oct 2013, 95(2):144-150.
75. Chen Y., Ge W., Xu L., Qu C., Zhu M., Zhang W., et al. miR-200b is involved in intestinal fibrosis of Crohn's disease. Int J Mol Med Apr 2012, 29(4):601-606.
76. Zhang B., Wang Z., Deng B., Wu X., Liu J., Feng X. Identification of Enolase 1 and Thrombospondin-1 as serum biomarkers in HBV hepatic fibrosis by proteomics. Proteome Sci 2013, 11(1):30.
77. Richards T.J., Kaminski N., Baribaud F., Flavin S., Brodmerkel C., Horowitz D., et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med Jan 1 2012, 185(1):67-76.
78. Nie S., Benito-Pena E., Zhang H., Wu Y., Walt D.R. Multiplexed salivary protein profiling for patients with respiratory diseases using fiber-optic bundles and fluorescent antibody-based microarrays. Anal Chem Oct 1 2013, 85(19):9272-9280.
79. Guerrot D., Dussaule J.C., Mael-Ainin M., Xu-Dubois Y.C., Rondeau E., Chatziantoniou C., et al. Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PLoS One 2012, 7(3):e31974.
80. Geboes K.P., Cabooter L., Geboes K. Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastroenterol Belg Oct 2000, 63(4):371-376.
81. Graham M.F., Diegelmann R.F., Elson C.O., Lindblad W.J., Gotschalk N., Gay S., et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology Feb 1988, 94(2):257-265.
82. Borley N.R., Mortensen N.J., Kettlewell M.G., George B.D., Jewell D.P., Warren B.F. Connective tissue changes in ileal Crohn's disease: relationship to disease phenotype and ulcer-associated cell lineage. Dis Colon Rectum Mar 2001, 44(3):388-396.
83. Wegrowski J., Lafuma C., Lefaix J.L., Daburon F., Robert L. Modification of collagen and noncollagenous proteins in radiation-induced muscular fibrosis. Exp Mol Pathol Jun 1988, 48(3):273-285.
84. Geboes K., El-Zine M.Y., Dalle I., El-Haddad S., Rutgeerts P., Van Eyken P. Tenascin and strictures in inflammatory bowel disease: an immunohistochemical study. Int J Surg Pathol Oct 2001, 9(4):281-286.
85. Koukoulis G., Ke Y., Henley J.D., Cummings O.W. Obliterative muscularization of the small bowel submucosa in Crohn disease: a possible mechanism of small bowel obstruction. Arch Pathol Lab Med Oct 2001, 125(10):1331-1334.
86. Shelley-Fraser G., Borley N.R., Warren B.F., Shepherd N.A. The connective tissue changes of Crohn's disease. Histopathology Jun 2012, 60(7):1034-1044.
87. Shepherd N.A., Jass J.R. Neuromuscular and vascular hamartoma of the small intestine: is it Crohn's disease?. Gut Dec 1987, 28(12):1663-1668.
88. Breynaert C., Dresselaers T., Perrier C., Arijs I., Cremer J., Van Lommel L., et al. Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease. PLoS One 2013, 8(7):e68876.
89. Lawrance I.C., Maxwell L., Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis Aug 2001, 7(3):226-236.
90. Maccioni F., Staltari I., Pino A.R., Tiberti A. Value of T2-weighted magnetic resonance imaging in the assessment of wall inflammation and fibrosis in Crohn's disease. Abdom Imaging Dec 2012, 37(6):944-957.
91. Punwani S., Rodriguez-Justo M., Bainbridge A., Greenhalgh R., De Vita E., Bloom S., et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology Sep 2009, 252(3):712-720.
92. Fornasa F., Benassuti C., Benazzato L. Role of magnetic resonance enterography in differentiating between fibrotic and active inflammatory small bowel stenosis in patients with Crohn's disease. J Clin Imaging Sci 2011, 1:35.
93. Adler J., Punglia D.R., Dillman J.R., Polydorides A.D., Dave M., Al-Hawary M.M., et al. Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn's disease. Inflamm Bowel Dis May 2012, 18(5):849-856.
94. Larsson A.E., Melgar S., Rehnstrom E., Michaelsson E., Svensson L., Hockings P., et al. Magnetic resonance imaging of experimental mouse colitis and association with inflammatory activity. Inflamm Bowel Dis Jun 2006, 12(6):478-485.
95. Mustafi D., Fan X., Dougherty U., Bissonnette M., Karczmar G.S., Oto A., et al. High-resolution magnetic resonance colonography and dynamic contrast-enhanced magnetic resonance imaging in a murine model of colitis. Magn Reson Med Apr 2010, 63(4):922-929.
96. Quarles C.C., Lepage M., Gorden D.L., Fingleton B., Yankeelov T.E., Price R.R., et al. Functional colonography of Min mice using dark lumen dynamic contrast-enhanced MRI. Magn Reson Med Sep 2008, 60(3):718-726.
97. Young M.R., Ileva L.V., Bernardo M., Riffle L.A., Jones Y.L., Kim Y.S., et al. Monitoring of tumor promotion and progression in a mouse model of inflammation-induced colon cancer with magnetic resonance colonography. Neoplasia Mar 2009, 11(3):237-246. [1 pp.].
98. Ripolles T., Rausell N., Paredes J.M., Grau E., Martinez M.J., Vizuete J. Effectiveness of contrast-enhanced ultrasound for characterisation of intestinal inflammation in Crohn's disease: a comparison with surgical histopathology analysis. J Crohns Colitis Mar 2013, 7(2):120-128.
99. Nylund K., Jirik R., Mezl M., Leh S., Hausken T., Pfeffer F., et al. Quantitative contrast-enhanced ultrasound comparison between inflammatory and fibrotic lesions in patients with Crohn's disease. Ultrasound Med Biol Jul 2013, 39(7):1197-1206.
100. Kim K., Jeong C.G., Hollister S.J. Non-invasive monitoring of tissue scaffold degradation using ultrasound elasticity imaging. Acta Biomater Jul 2008, 4(4):783-790.
101. Kim K., Johnson L.A., Jia C., Joyce J.C., Rangwalla S., Higgins P.D., et al. Noninvasive ultrasound elasticity imaging (UEI) of Crohn's disease: animal model. Ultrasound Med Biol Jun 2008, 34(6):902-912.
102. Stidham R.W., Xu J., Johnson L.A., Kim K., Moons D.S., McKenna B.J., et al. Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. Gastroenterology Sep 2011, 141(3):819-826.
103. van Swelm R.P., Laarakkers C.M., Kooijmans-Otero M., de Jong E.M., Masereeuw R., Russel F.G. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. Toxicol Lett Aug 29 2013, 221(3):219-224.
104. Hirasawa Y., Kohno N., Yokoyama A., Inoue Y., Abe M., Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol Oct 1997, 17(4):501-507.
105. Ohnishi H., Yokoyama A., Kondo K., Hamada H., Abe M., Nishimura K., et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med Feb 1 2002, 165(3):378-381.
106. Greene K.E., King T.E., Kuroki Y., Bucher-Bartelson B., Hunninghake G.W., Newman L.S., et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J Mar 2002, 19(3):439-446.
107. Samukawa T., Hamada T., Uto H., Yanagi M., Tsukuya G., Nosaki T., et al. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D. BMC Pulm Med 2012, 12:55.
108. Zhu H., Luo H., Zuo X. MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma. Exp Mol Med 2013, 45:e41.
109. Hunzelmann N., Risteli J., Risteli L., Sacher C., Vancheeswaran R., Black C., et al. Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma?. Br J Dermatol Dec 1998, 139(6):1020-1025.
110. Yazawa N., Kikuchi K., Ihn H., Fujimoto M., Kubo M., Tamaki T., et al. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol Jan 2000, 42(1 Pt 1):70-75.
111. Ishikawa N., Hattori N., Yokoyama A., Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Invest Mar 2012, 50(1):3-13.
112. Kinder B.W., Brown K.K., McCormack F.X., Ix J.H., Kervitsky A., Schwarz M.I., et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest Jun 2009, 135(6):1557-1563.
113. STX-100 in patients with idiopathic pulmonary fibrosis (IPF) May 14 2013, visited January 13 2014. http://clinicaltrials.gov/show/NCT01371305.
114. Safety and efficacy of BIBF 1120 at high dose in idiopathic pulmonary fibrosis patients October 15, 2013; visited January 13, 2014. http://clinicaltrials.gov/show/NCT01335464.
115. Kawakami T., Ihn H., Xu W., Smith E., LeRoy C., Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol Jan 1998, 110(1):47-51.
116. Krieg T., Langer I., Gerstmeier H., Keller J., Mensing H., Goerz G., et al. Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol Dec 1986, 87(6):788-791.
117. Badra G., Lotfy M., El-Refaie A., Obada M., Abdelmonem E., Kandeel S., et al. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. Acta Microbiol Immunol Hung Mar 2010, 57(1):29-42.
118. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation?. J Hepatol Apr 2005, 42(4):448-456.
119. Manzia T.M., Angelico R., Toti L., Bellini M.I., Sforza D., Palmieri G., et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int May 2011, 24(5):461-468.
120. Sanchez-Fueyo A., Restrepo J.C., Quinto L., Bruguera M., Grande L., Sanchez-Tapias J.M., et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation Jan 15 2002, 73(1):56-63.
121. Sethna C., Benchimol C., Hotchkiss H., Frank R., Infante L., Vento S., et al. Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant 2011, 2011:389542.